Hong Kong Med J 2022;28(6):424-6 | Epub 18 Nov 2022
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
EDITORIAL
Combating antimicrobial resistance in Hong
Kong: where are we and where should we go?
Edmond SK Ma1,2, MD, FHKAM (Community Medicine)
1 Epidemiology Adviser, Hong Kong Medical Journal
2 Infection Control Branch, Centre for Health Protection, Department of Health, Hong Kong SAR Government
Corresponding author: Dr Edmond SK Ma (edmond_sk_ma@dh.gov.hk)
Antimicrobial resistance (AMR) has been declared
one of the top ten global public health threats facing
humanity by the World Health Organization (WHO)
in 2019.1 The WHO has estimated that, by 2050, the
number of deaths attributed to AMR will be as high
as 10 million each year, exceeding those caused by
cancer (8.2 million).2 The coronavirus disease 2019
(COVID-19) pandemic has exacerbated the AMR
situation globally. In 2020, the Centers for Disease
Control and Prevention of the United States reported
more cases of carbapenem-resistant Acinetobacter
(increased by 78%), antifungal-resistant Candida
auris (increased by 60%), and carbapenem-resistant
Enterobacterales (increased by 35%) than in 2019,
possibly due to more and sicker patients during the
pandemic who required more frequent and longer
use of catheters and ventilators, personal protective
equipment and laboratory supply challenges,
fewer healthcare staff, and longer lengths of stay.3
Outbreaks of multidrug-resistant organisms,
including carbapenem-resistant Acinetobacter
baumannii,4 5 C auris6 and Enterobacterales,7 as
well as vancomycin-resistant Enterococcus,8 9
have been reported in healthcare facilities. In a
systematic review that identified 17 outbreaks
during the COVID-19 pandemic caused mainly by
carbapenem-resistant Acinetobacter baumannii and
C auris, inadequate personal protective equipment
or hand hygiene adherence, personal protective
equipment shortage, and high antibiotic use were
the most commonly reported modifiable factors
contributing to the outbreaks.10 In some countries,
antimicrobial stewardship programmes in hospitals
were adversely affected or even suspended.11 12
Hong Kong is not immune to these challenges, and
substantial resource have been diverted to tackle the
COVID-19 pandemic.
Despite these constraints, considerable
progress has been made in Hong Kong, according to
directives as described in the Hong Kong Strategy
and Action Plan on Antimicrobial Resistance
(2017-2022).13 The AMR Information System was
established in October 2021 to collate, analyse, and
report data from various departments of the Hong
Kong SAR Government and the Hospital Authority.
This system provides well-organised and transparent access to surveillance data on the human side covering
AMR and antimicrobial use (AMU). Antimicrobial
resistance and AMU involving food animals are also
now included in a regular surveillance programme,
and a long-term food surveillance system on AMR
has been established. Enhanced regulatory measures
against the illegal sale of antimicrobials, health
promotional activities, and collaboration between
healthcare providers and community partners to
advocate appropriate use of antimicrobials have
been effective. The percentage of total supply of
antibiotics to community pharmacies gradually
decreased from around 18.5% in 2016 to 5.6% in
2021. Under the Antibiotic Stewardship Programme
in Primary Care initiative, new guidance notes
and patient information sheets on seven common
infections have been developed to drive appropriate
antibiotic use by primary care doctors. Coupled
with antimicrobial stewardship programmes
implemented in hospitals, the proportion of the total
antimicrobial supply classified as the “Access” group
under WHO classification (ie, those showing lower
resistance potential than antibiotics in the other
groups) reached 61.9% in 2020 and 65.8% in 2021 in
Hong Kong, above the 60% target set by the WHO.
Data from the Hospital Authority in 2021 reflected
that 94.5% use of two broad spectrum antibiotics,
namely piperacillin/tazobactam and meropenem,
were found to be appropriately used in medical,
surgical and orthopaedic and traumatology specialty
of acute hospitals.14
The Hong Kong SAR Government is also
tackling AMR on other fronts. For animal health, a
policy is being prepared for “veterinary prescription-only
medication supply”.14 To reduce the incidence of
infection, infection prevention and control training
is in place, with over 30 000 attendances per year
in the human health sector and 6000 in the food
sector. The Department of Health has also been
offering free seasonal influenza vaccination and
pneumococcal vaccination to eligible target groups,
which helps reduce potential complications from
these diseases, such as secondary bacterial infections
and AMU. Under the “One Health” framework, the
Department of Health, the Agriculture, Fisheries
and Conservation Department, and the Food and Environmental Hygiene Department have joined
together to launch publicity activities to echo the
annual World Antibiotic Awareness Week to promote
proper use of antibiotics. To encourage research,
AMR has been included as one of the thematic
priorities in the open call for investigator-initiated
projects under the Health and Medical Research
Fund, and 33 related projects have been funded in
the 2017 to 2020 round of open call applications.
Nevertheless, many challenges to further
improve the AMR situation remain. A sustained high
rate of methicillin-resistant Staphylococcus aureus
bacteraemia was detected after 48 hours of admission
in public hospitals in the past few years. Data reported
to the Centre for Health Protection indicate that
the number of cases of carbapenemase-producing
Enterobacteriaceae discharged to residential care
homes for the elderly has been doubled from
242 cases in 2019 to 526 cases in 2021. Since the first
case of C auris, an emerging multidrug-resistant
fungus, reported in Hong Kong in July 2019, more
cases and outbreaks in public hospitals have been
reported.15 16 Despite a reduction of AMU among
community pharmacies and general practitioners in
2020 and 2021, it is possible for rebound of respiratory
illnesses and resurge of AMU in these settings after
relaxation of public health measures for COVID-19.
Health promotion on AMR is still needed: in a
survey of the general public, 54.0% of respondents
mistakenly identified cold and flu as treatable with
antibiotics.17 Moreover, comprehensive data on
AMU and AMR among general practitioners are
lacking. There is also limited scientific knowledge on
the role of the environment in the evolution of AMR.
In his Policy Address on 19 October 2022,
the Chief Executive of Hong Kong pledged to
promulgate a new plan on AMR for the next 5 years.
To tackle this public health threat and address
challenges ahead, Hong Kong Strategy and Action
Plan on Antimicrobial Resistance (2023-2027)14
adopts six key policy areas: strengthen knowledge
through surveillance and research; optimise use
of antimicrobials in humans and animals; reduce
incidence of infection through effective sanitation,
hygiene and prevention measures; improve awareness
and understanding of AMR through effective
communication, education and training; promote
research on AMR; and strengthen partnerships
and foster engagement of relevant stakeholders.
Among the 21 objectives in the Action Plan, five are
identified as priority interventions: surveillance and
control of AMR in ready-to-eat food; strengthening
regulation of record keeping for prescription-only
antimicrobials in community pharmacies;
enhancement of antimicrobial stewardship
programme in public hospitals; a territory-wide
decolonisation programme for multidrug-resistant
organism in residential care homes for the elderly; and conducting regular surveys among the general
public on AMR to inform strategies on health
promotion.
The theme for the 2022 World Antibiotic
Awareness Week (18-24 November) is “Contribute
Together to Combat Antimicrobial Resistance!”.
Antimicrobial resistance is everyone’s business.
The Hong Kong Centre for Health Protection has
a dedicated page (https://www.chp.gov.hk/en/features/47850.html) with the latest information on
AMR for the general public and healthcare workers.
With concerted effort from healthcare professionals
and all other concerned parties, we can combat
AMR together in the coming 5 years and beyond.
Author contributions
The author contributed to the editorial, approved the final version for publication, and takes responsibility for its
accuracy and integrity.
Conflicts of interest
The author has declared no conflict of interest.
References
1. World Health Organization. Ten threats to global health
in 2019. Available from: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019. Accessed
22 Oct 2022.
2. World Health Organization. Factsheet: Antimicrobial
resistance. July 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.
Accessed 22 Oct 2022.
3. Centers for Disease Control and Prevention. COVID-19:
U.S. Impact on Antimicrobial Resistance, Special Report
2022. Available from: https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf. Accessed on 22 Oct 2022.
4. Shinohara DR, Dos Santos Saalfeld SM, Martinez HV, et al.
Outbreak of endemic carbapenem-resistant Acinetobacter
baumannii in a coronavirus disease 2019 (COVID-19)–specific intensive care unit. Infect Control Hosp Epidemiol
2022;43:815-7. Crossref
5. Perez S, Innes GK, Walters MS, et al. Increase in hospital-acquired
carbapenem-resistant Acinetobacter baumannii
infection and colonization in an acute care hospital during
a surge in COVID-19 admissions—New Jersey, February–
July 2020. MMWR Morb Mortal Wkly Rep 2020;69:1827-31. Crossref
6. Villanueva-Lozano H, de Treviño-Rangel RJ, González GM, et al. Outbreak of Candida auris infection in a COVID-19
hospital in Mexico. Clin Microbiol Infect 2021;27:813-6. Crossref
7. García-Meniño I, Forcelledo L, Rosete Y, García-Prieto E,
Escudero D, Fernández J. Spread of OXA-48-producing
Klebsiella pneumoniae among COVID-19-infected
patients: the storm after the storm. J Infect Public Health
2021;14:50-2. Crossref
8. Kampmeier S, Tönnies H, Correa-Martinez CL, Mellmann
A, Schwierzeck V. A nosocomial cluster of vancomycin
resistant enterococci among COVID-19 patients in an
intensive care unit. Antimicrob Resist Infect Control 2020;9:154.Crossref
9. Rathod SN, Bardowski L, Tse I, et al. Vancomycin-resistant
Enterococcus (VRE) outbreak in a pre- and
post-cardiothoracic transplant population: impact of
discontinuing multidrug-resistant organism (MDRO)
surveillance during the COVID-19 pandemic. Transpl
Infect Dis 2022 Sep 28. Epub ahead of print. Crossref
10. Thoma R, Seneghini M, Seiffert SN, et al. The challenge of
preventing and containing outbreaks of multidrug-resistant
organisms and Candida auris during the coronavirus
disease 2019 pandemic: report of a carbapenem-resistant
Acinetobacter baumannii outbreak and a systematic
review of the literature. Antimicrob Resist Infect Control
2022;11:12. Crossref
11. Comelli A, Genovese C, Lombardi A, et al; ASP Lomb Study
Group. What is the impact of SARS-CoV-2 pandemic on
antimicrobial stewardship programs (ASPs)? The results of
a survey among a regional network of infectious disease
centres. Antimicrob Resist Infect Control 2022;11:108. Crossref
12. Ashiru-Oredope D, Kerr F, Hughes S, et al. Assessing
the impact of COVID-19 on antimicrobial stewardship
activities/programs in the United Kingdom. Antibiotics
(Basel) 2021;10:110. Crossref
13. Hong Kong SAR Government. Hong Kong Strategy and
Action Plan on Antimicrobial Resistance 2017-2022. 2017.
Available from: https://www.chp.gov.hk/files/pdf/amr_action_plan_eng.pdf. Accessed 22 Oct 2022.
14. Hong Kong SAR Government. Hong Kong Strategy
and Action Plan on Antimicrobial Resistance 2023-2027. 2022. Available from: https://www.chp.gov.hk/files/pdf/amr_action_plan_eng_2023.pdf. Accessed 17 Nov 2022.
15. Centre for Health Protection, Department of Health, Hong
Kong SAR Government. Alert on the rise in Candida
auris colonisation in Hong Kong (letter to doctors).
Available from: https://www.chp.gov.hk/files/pdf/lti_c_auris_20201015_eng.pdf. Accessed 22 Oct 2022.
16. Hong Kong SAR Government press release. Update
on cluster of Candida auris cases in Princess Margaret
Hospital. Available from: https://www.info.gov.hk/gia/general/202205/30/P2022053000624.htm. Accessed 22 Oct 2022.
17. Centre for Health Protection, Department of Health, Hong
Kong SAR Government. General public’s knowledge,
attitude and practice survey on antimicrobial resistance
2016/17. Available from: https://www.chp.gov.hk/en/static/51310.html. Accessed 22 Oct 2022.